Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...